About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Chicago | 20,493 Studies Near You | Clareo Health

Clinical Trials LocationsChicago

Clinical Trials in Chicago

Discover 20,493 clinical trials near Chicago, Illinois. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 5681-5700 of 20,493 trials

Active Not RecruitingPhase 32.2 miles

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

NCT06046820

The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.

Ectonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic RicketsGeneralized Arterial Calcification of Infancy

Inozyme Pharma27 participantsStarted Nov 2023

Aurora, Colorado, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +12 more locations

Active Not RecruitingNA2.2 miles

Improving Sleep in Gynecologic Cancer Survivors

NCT05044975

This purpose of this study is to learn about how to provide treatment to gynecologic cancer survivors who have difficulty sleeping.

Sleep DisturbanceGynecologic Cancer

University of Arizona95 participantsStarted Oct 2021

Tucson, Arizona, United States • Chicago, Illinois, United States

Find Trials by Condition in Chicago

Breast Cancerin Chicago Lung Cancerin Chicago Prostate Cancerin Chicago Colorectal Cancerin Chicago Melanomain Chicago Leukemiain Chicago Lymphomain Chicago Pancreatic Cancerin Chicago Ovarian Cancerin Chicago Brain Cancerin Chicago Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 32.2 miles

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT02076009

The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Multiple Myeloma

Janssen Research & Development, LLC569 participantsStarted Jul 2014

Little Rock, Arkansas, United States • Gainesville, Florida, United States • West Palm Beach, Florida, United States +142 more locations

Active Not RecruitingNA2.2 miles

Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis

NCT02089880

The study will specifically evaluate the potential of the C-Brace to improve the functional mobility and quality of life in individuals with lower extremity impairments due to neurologic or neuromuscular disease, orthopedic disease or trauma, as compared to the stance control orthosis.

Spinal Cord InjuriesPoliomyelitisPost-polio Syndrome+2 more

Shirley Ryan AbilityLab24 participantsStarted Feb 2014

Chicago, Illinois, United States

RECRUITING2.2 miles

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT06950788

The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation. The question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced measurements such as wrist actigraphy, continuous glucose monitoring, or oral glucose tolerance testing predict the development of diabetes after liver transplant? Participants will be asked to periodically participate in wearing a continuous glucose monitor and wrist actigraph and obtain an oral glucose tolerance test both before and after liver transplant.

Cirrhosis, LiverDiabetes Mellitus RiskTransplant; Failure, Liver+1 more

University of Chicago60 participantsStarted Mar 2024

Chicago, Illinois, United States

COMPLETEDPhase 12.2 miles

Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma

NCT03011671

This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation (IR)). During this study, patients will receive daily oral ACZ with TMZ. During each cycle, ACZ will be started on the day of TMZ initiation and continued for a total of 21 days.

Malignant Glioma of Brain

University of Chicago10 participantsStarted Oct 2018

Chicago, Illinois, United States

RECRUITINGNA125 miles

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

NCT02235857

Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g, proteinuria and hypoproteinemia). Although the definitive mechanism by which the system may relieve nephrotic syndrome is unknown, it has been recognized as one of alternative therapies for refractory nephrotic syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology. This study is conducted as a post approval study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the treatment of drug-resistant pediatric primary FSGS.

Focal Segmental Glomerulosclerosis

Kaneka Medical America LLC35 participantsStarted May 2015

Loma Linda, California, United States • Los Angeles, California, United States • Wilmington, Delaware, United States +9 more locations

RECRUITINGNA125 miles

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

NCT04503395

The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).

Aortic Aneurysm, Abdominal

FCRE (Foundation for Cardiovascular Research and Education)204 participantsStarted May 2021

La Jolla, California, United States • Stanford, California, United States • Gainesville, Florida, United States +29 more locations

COMPLETEDPhase 3165 miles

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

NCT05412004

The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2.

Obstructive Sleep ApneaObesity

Eli Lilly and Company469 participantsStarted Jun 2022

Riverside, California, United States • Brandon, Florida, United States • Ocala, Florida, United States +55 more locations

COMPLETEDPhase 2201 miles

A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

NCT00447980

The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia. This research is being done because there are no effective therapies for people with these retinal degenerations. They are genetic disorders that affect one's ability to see at night, and later cause tunnel vision and loss of central vision. Retinal degenerations affect the retina, a light sensitive layer of cells in the back of the eye. Slowly over time, these cells die and cause permanent loss of vision. The implant is a small capsule that contains human retinal pigment epithelium cells. These cells have been given the ability to make CNTF and release it through the capsule membrane into the surrounding fluid. In this study, two different CNTF dose levels will be used: a high dose and a low dose in one eye, as well as a sham (or placebo) surgery in the other eye.

Retinitis Pigmentosa

Neurotech Pharmaceuticals73 participantsStarted Jan 2007

Beverly Hills, California, United States • Sacramento, California, United States • San Francisco, California, United States +9 more locations

TERMINATEDPhase 1237 miles

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05757492

This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous \[NSCLC-NS\] and Hepatocellular carcinoma \[HCC\])

Advanced Solid TumorNon-Small Cell Lung CancerHepatocellular Carcinoma

Coherus Oncology, Inc.22 participantsStarted Apr 2023

Orlando, Florida, United States • Detroit, Michigan, United States • Reno, Nevada, United States +1 more locations

Active Not RecruitingPhase 1/2269 miles

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

NCT05664243

This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.

In8bio Inc.4 participantsStarted Sep 2023

Birmingham, Alabama, United States • Tampa, Florida, United States • Louisville, Kentucky, United States +2 more locations

RECRUITINGNA276 miles

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06455475

This randomized controlled study evaluates the adjuvant use of Derm-Maxx in patients with diabetic foot ulcers

Diabetic Foot Ulcer

Capsicure, LLC150 participantsStarted Oct 2024

Athens, Alabama, United States • Encino, California, United States • Hollywood, Florida, United States +8 more locations

AVAILABLE276 miles

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

NCT05572970

This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.

Birmingham, Alabama, United States • Tucson, Arizona, United States • Newport Beach, California, United States +4 more locations

Active Not RecruitingNA286 miles

Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions

NCT03998657

This extended clinical investigation is a multicenter, prospective, single arm study intended to provide continued access of the Exablate Model 2100 device (Exablate Prostate) to patients for treatment of prostate lesions and collect additional safety and effectiveness data during the 510(k) preparation and review period.

Prostate Cancer

InSightec14 participantsStarted Dec 2019

Stanford, California, United States • Delray Beach, Florida, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 2414 miles

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

NCT04129164

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

Sjögren's Syndrome

Amgen183 participantsStarted Dec 2019

Fullerton, California, United States • Upland, California, United States • Lawrenceville, Georgia, United States +59 more locations

COMPLETEDPhase 2436 miles

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

NCT05570305

The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.

Chronic Kidney Diseases

University Medical Center Groningen42 participantsStarted Oct 2022

Aurora, Colorado, United States • Toronto, Ontario, Canada • Montreal, Quebec, Canada +4 more locations

COMPLETEDPhase 1711 miles

Study of AGEN1571 in Participants With Advanced Solid Tumors

NCT05377528

This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of AGEN1571 both as a monotherapy and in combination with balstilimab (PD-1 inhibitor) and/or botensilimab (2-agent combination or 3-agent combination) in participants diagnosed with advanced solid tumors. Part 1 will be the dose escalation phase to determine the RP2D of AGEN1571 monotherapy or AGEN1571 in combination with balstilimab and/or botensilimab. Part 2 will be the dose expansion phase for specific disease indications. Participants will receive study treatment for up to 2 years, or until any disease progression, unacceptable toxicity, or participant wishes to withdraw consent for any reason.

Advanced Solid Tumor

Agenus Inc.22 participantsStarted Jul 2022

Los Angeles, California, United States • Denver, Colorado, United States • Sarasota, Florida, United States +3 more locations

COMPLETEDNA814 miles

A Digital Intervention to Improve Physical Activity and Sleep Behaviors in Youth With Psychiatric Diagnoses

NCT05505578

The goal of "GamerFit" is to test the delivery of a theory-based mHealth app that utilizes social support, exergaming, and telehealth coaching to improve PA levels, sleep, and psychiatric symptoms among youth participants (ages 13-17 y) with PD. In order to aid future intervention optimization, up to 65 participants with at least one PD will be randomized, with 30-35 using the GamerFit app with weekly telehealth coaching sessions and 30-35 using a commercial healthy habits app as a comparator group

Psychiatric Diagnosis

Pennington Biomedical Research Center62 participantsStarted Jan 2023

Baton Rouge, Louisiana, United States • North Andover, Massachusetts, United States

RECRUITINGNA916 miles

An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

NCT06098482

The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.

Cochlear46 participantsStarted Feb 2024

Lone Tree, Colorado, United States • Melbourne, Victoria, Australia • Antwerp, Antwerp, Belgium +1 more locations

PreviousPage 285 of 1025Next

in Chicago

Heart Diseasein Chicago